ӳ��ý

Cancer Program

CRISPR-based therapeutic genome editing for inherited blood disorders.

Levesque S, Bauer DE. CRISPR-based therapeutic genome editing for inherited blood disorders. Nature reviews. Drug discovery. 2025. doi:10.1038/s41573-025-01236-y

SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors.

Lightbody ED, Sklavenitis-Pistofidis R, Wu T, et al. SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors. Nature cancer. 2025. doi:10.1038/s43018-025-01006-0

A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas.

Apfelbaum AA, Morin E, Sturm D, et al. A diverse landscape of FGFR alterations and co-mutations suggests potential therapeutic strategies in pediatric low-grade gliomas. Nature communications. 2025;16(1):7018. doi:10.1038/s41467-025-61820-z

In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma.

Knudsen NH, Escobar G, Korell F, et al. In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma. Nature. 2025. doi:10.1038/s41586-025-09489-8

Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation.

Słabicki M. Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation. Molecular cell. 2025;85(16):3184-3201.e14. doi:10.1016/j.molcel.2025.07.019

A multimodal whole-slide foundation model for pathology.

Ding T, Wagner SJ, Song AH, et al. A multimodal whole-slide foundation model for pathology. Nature medicine. 2025. doi:10.1038/s41591-025-03982-3

Pancreatic cancer risk prediction using deep sequential modeling of longitudinal diagnostic and medication records.

Zheng C, Khan A, Ritter D, et al. Pancreatic cancer risk prediction using deep sequential modeling of longitudinal diagnostic and medication records. Cell reports. Medicine. 2025;6(9):102359. doi:10.1016/j.xcrm.2025.102359

Helicase-assisted continuous editing for programmable mutagenesis of endogenous genomes.

Chen XD, Chen Z, Wythes G, et al. Helicase-assisted continuous editing for programmable mutagenesis of endogenous genomes. Science (New York, N.Y.). 2024;386(6718):eadn5876. doi:10.1126/science.adn5876

The next big questions in cancer research.

Loi S, Settleman J, Joyce JA, et al. The next big questions in cancer research. Cell. 2023;186(8):1523-1527. doi:10.1016/j.cell.2023.01.037

Targeting TBK1 to overcome resistance to cancer immunotherapy.

Sun Y, Revach OY, Anderson S, et al. Targeting TBK1 to overcome resistance to cancer immunotherapy. Nature. 2023. doi:10.1038/s41586-023-05704-6